ESC 2022 | PERSPECTIVE: Efficacy and Safety of Sacubitril/Valsartan Compared with Valsartan in Cognitive Function of Patients with Cardiac Failure and Preserved Function

About 30 to 80% of patients with heart failure (HF) have some sort of cognitive impairment, with a higher risk of dementia than the general population. 

ESC 2022 |

A component of sacubitril/valsartan inhibits neprilysin—an enzyme involved in amyloid-β peptide degradation (Alzheimer’s disease)—, and that could worsen cognitive impairment.

The PERSPECTIVE study is the first randomized trial to assess the long-term effects of sacubitril/valsartan compared with valsartan on the cognitive function of patients with HF and an ejection fraction >40%.

In this study, 592 patients from 137 sites in 20 countries were randomized 1:1. Mean patient age was 72.4 years old, and 46.8% of subjects were female. The primary endpoint (PEP) was cognitive function change at three years, as assessed through the CogState score (GCCS).

There were no significant differences in the PEP when compared with patients treated with valsartan. The analysis was made using the least square mean, with a difference of 0.080 (95% confidence interval: 0.1230-0.0870; p = 0.74). 

Read also: ESC 2022 | SECURE Trial.

In turn, an evaluation of the β-amyloid peptide deposition in the brain was conducted using PET, showing less deposition in patients treated with sacubitrile/valsartan. 

Dr McMurray posited that this study evidences the safety of sacubitrile/valsartan treatment in terms of cognitive function in HF patients.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Font: McMurray J. Neprilysin inhibition does not affectcognitive function in patientswith heart failure (PERSPECTIVE Trial). Presentado en Congreso Europeo de Cardiología ESC 2022. Agosto 26, 2022. Barcelona, España.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...